CD80 antibody
Quick Overview for CD80 antibody (ABIN7670164)
Target
See all CD80 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purpose
- AF/LE Purified Anti-Human CD80 Antibody[2D10]
-
Endotoxin Level
- Low Endotoxin
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- ≥ 1 mg/mL
-
Buffer
- Sterile PBS. < 1.0 EU per mg of the antibody as determined by the LAL method.
-
Preservative
- Azide free
-
Handling Advice
- avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C valid for 12 months or -20°C valid for long term storage, avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
-
Expiry Date
- 12 months
-
-
- CD80
-
Alternative Name
- CD80
-
Background
- LAB,CTLA-4 counter-receptor B,T-lymphocyte activation antigen CD,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7,CD80,CD28LGB7-1 antigen,T-lymphocyte activation antigen CD80,Activation B7-1 antigen,CTLA-4 counter-receptor B7.1, B7-1, BB1,B lymphocyte activation antigen B7,B7-1 antigen,B7-1 antigen),CD28 antigen ligand 1,CD80 antigen,CD80 antigen (CD28 antigen ligand 1,CD80 Molecule,Costimulatory factor CD80,costimulatory molecule variant IgV-CD80,B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages.
-
UniProt
- P33681
-
Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-